EB06 / LightChain Bioscience, Edesa Biotech - LARVOL DELTA

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results (GlobeNewswire) - "During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study in moderate-to-severe nonsegmental vitiligo. The company anticipates recruitment will begin midyear 2026, subject to regulatory approvals."

Commercial • New P2 trial • Vitiligo

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results (GlobeNewswire) - "During the quarter, the company advanced its main asset, EB06...with data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company intends to pursue an investigational new drug (IND) application for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients. Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA."

FDA filing • New P2 trial • P2 data • Vitiligo

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) - "Edesa Biotech, Inc...today announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred shares...and 3,468,746 common shares in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The purchase price per Preferred Share was $10,000 and the purchase price per common share was $1.92. Officers and directors of the Company purchased approximately $1.1 million of the securities sold in the offering...Edesa currently expects to use the net proceeds from the offering, to fund the continued advancement of EB06, its CXCL10 monoclonal antibody, into a Phase 2 clinical study in subjects with nonsegmental vitiligo, and for working capital and general corporate purposes."

Financing • Vitiligo